Previous Study: TRIO042
Next Study: TRIO040

Studies & Results


A phase III, multicenter, randomized, open-label trial to evaluate the efficacy and safety of regorafenib in combination with nivolumab versus transarterial chemoembolization (TACE) for the first-line treatment of intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at